&w=3840&q=100)
Rekha Jhunjhunwala portfolio stock: Indian Hotels drops 5% post Q4 results
Indian Hotels share price today
Rekha Jhunjhunwala-owned stock, Indian Hotels Company, dropped as much as 5 per cent on the BSE in Tuesday's intraday trade after the hotel stock reported its March 2025 results.
Indian Hotels Company share price slipped 4.9 per cent to hit an intraday low of ₹762.4 per share on the BSE. As many as 0.26 million shares have changed hands on the counter on the exchange, as against a two-week average of 0.098 million shares.
Why are Indian Hotels shares down today?
Indian Hotels shares fell in the stock market today after various brokerages said that the Jhunjhunwala portfolio stock has limited upside from here, given that most of the positives are priced in.
Most brokerages have maintained their ratings and share price targets on Indian Hotels stock, despite the company posting strong results for Q4FY25, given the rich valuations.
Indian Hotels Q4 results 2025
(Y-o-Y). This was led by growth in the Hotels segment (13 per cent Y-o-Y with 14 per cent rise in average room rate (ARR) and 15.5 per cent Revenue per available room (RevPAR)).
Further, Indian Hotels posted a consolidated Ebitda and adjusted net profit growth of 30 per cent and 26 per cent Y-o-Y, respectively, at ₹860 crore and ₹520 crore.
Indian Hotels' new business verticals, comprising Ginger, Qmin, and amã Stays & Trails grew 40 per cent Y-o-Y to ₹600 crore in FY25, while TajSATs posted 17 per cent Y-o-Y growth to ₹1,050 crore. Chambers reported revenue of ₹150 crore, up 25 per cent Y-o-Y. READ MORE
Rekha Jhunjhunwala Portfolio Stock
At the end of the March 2025 quarter, Rekha Jhunjhunwala, wife of late ace investor Rakesh Jhunjhunwala, owned 1 per cent stake in Indian Hotels Company.
Indian Hotels stock analysis, price target
Elara Capital sees 7% upside in Indian Hotels stock
Indian Hotels has guided for ₹1,200 crore capex in FY26. Of this, 60–65 per cent will be allocated towards major renovations and digital upgrades, while the remainder will go towards greenfield developments.
Moreover, the company has 15,900 keys in the managed hotel pipeline, of which 2,959 and 3,251 keys are likely to be opened in FY26 and FY27, respectively. The brokerage expects accelerated growth in management fee to continue as new hotel openings from management contract in FY26 and FY27 are tilted towards high-end brands such as Taj, SeleQtions and Vivanta.
"We have reduced Indian Hotels' Ebitda estimates by 3 per cent each for FY26 and FY27 to factor in lower margin for Taj SATS, to realign our RevPAR growth assumption. We reiterate 'Accumulate' rating with a share price target of ₹861 (unchanged)," it said.
Motilal Oswal maintains 'Buy'
Indian Hotels has maintained its double-digit revenue guidance, supported by strong structural tailwinds in the industry, with demand consistently outpacing supply.
Growth is further driven by rising Foreign Tourist Arrivals (FTAs), increased MICE activity, expanding leisure tourism, and Indian Hotels' robust development pipeline.
"We expect Indian Hotels to continue its upward trajectory, with revenue/Ebitda/adjusted PAT CAGR of 16 per cent/22 per cent/22 per cent over FY25-27E. We broadly maintain our FY26/FY27 Ebitda estimates," it said with a share price target of ₹940.
Nuvama Institutional Equities maintains 'Reduce'
Based on the Q4 performance, the brokerage has tweaked FY26/27 revenue and Ebitda estimates by 1 per cent and 2 per cent each, respectively. The brokerage has maintained its share price target of ₹628 and a 'Reduce' rating on the stock as its valuation has "run up much ahead of earnings".
YES Securities downgrades to 'Neutral'
The management has maintained its revenue growth in FY26E, driven by ARR. Generally, ARR growth results in better flow through to Ebitda, compared to occupancy-led growth, which can drive margin expansion.
For FY26, the management has guided for opening of 30 new properties, of which 3-4 properties will be owned. Total pipeline consists of ~19.5K keys, including ~15.9K managed keys. However, the near-term pipeline has been trimmed by ~925 keys, including ~250 owned keys, which can hamper near-term growth outlook.
"We pencil in Revenue/PAT CAGR of 16 per cent/22 per cent over FY25-27E. We value Indian Hotels Company stock at a premium to peer set, at FY27E EV/Ebitda multiple of 28x. Despite these factors, upside seems limited at 4-5 per cent," it said with a downgrade to 'Neutral' and a target price of ₹835.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
38 minutes ago
- Economic Times
GTL Infrastructure shares rally 42% in 2 days amid sectoral momentum
Traders chase momentum Live Events Mixed long-term returns, strong recent run Technical charts suggest momentum Fundamentals remain weak (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Shares of GTL Infrastructure surged 42% over the past two trading sessions, climbing as much as 18.7% on Thursday to Rs 2.16 on the BSE, as investors piled into the small-cap telecom infrastructure stock despite no fresh corporate rally is being driven by speculative interest and bullish technical indicators, alongside renewed optimism in the 5G infrastructure Thursday alone, nearly 66 crore GTL Infra shares changed hands on the NSE, highlighting elevated retail participation. The counter has drawn momentum-driven buying as broader markets turn favourable for small-cap infrastructure Wednesday, June 11, GTL Infrastructure had already posted a strong gain of 12.5% to Rs 1.71 as of 11:46 IST, emerging as the biggest gainer in the BSE's 'A' group. Volumes surged to 390.79 lakh shares, compared with a one-month average of 87.54 lakh Infra rose to the top of the volume leaderboard, driven by traders seeking short-term gains amid strong market momentum. Optimism surrounding telecom infrastructure, particularly the 5G rollout, along with a broader rally in small-cap infrastructure stocks, has fuelled interest in the recent enthusiasm, GTL Infrastructure's longer-term performance remains subdued. Over the last one year, shares are up just nearly 2%, while having declined 6.3% over the past six months. However, the short-term trend has turned sharply positive: the stock has gained 34% in the last three months and soared 39.3% in just the past one a technical perspective, GTL Infra is showing bullish momentum. The stock is trading above all eight of its key simple moving averages — the 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day SMAs — signalling strength across short-term and long-term indicators also point to sustained upside. The Relative Strength Index (RSI) stands at 79.8, well above the overbought threshold of 70, suggesting that a short-term pullback may be the Moving Average Convergence Divergence (MACD) is at 0, staying above both the center and signal lines, reinforcing the current bullish the company continues to struggle. In May, GTL Infrastructure reported a net loss of Rs 248.89 crore for the March 2025 quarter, widening from Rs 214.72 crore a year earlier. Revenue for the period rose marginally by 1.79% year-on-year to Rs 337.02 crore, while EBITDA grew 12.58% to Rs 49.22 crore.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)


Business Standard
39 minutes ago
- Business Standard
Zydus Life receives USFDA EIR for Gujarat facility
Zydus Lifesciences has informed that it has received the establishment inspection report (EIR) from the U.S Food and Drug Administration (USFDA) for its active pharmaceutical ingredient (API) manufacturing facility located in Ankleshwar, Gujarat. The inspection was conducted by the USFDA from March 10 to March 14, 2025. Following the review, the inspection has been classified as no action indicated (NAI). The USFDA has concluded that the inspection is now closed. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The companys consolidated net profit shed 0.96% to Rs 1,170.9 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24. Shares of Zydus Lifesciences shed 0.36% to Rs 975.20 on the BSE.
&w=3840&q=100)

Business Standard
39 minutes ago
- Business Standard
Asian Paints shares rise 3% after large deal in pre-open; all details here
Asian Paints share price gained 2.5 per cent in trade on Thursday, June 12, 2025, logging an intraday high at ₹2,263.95 per share on BSE. The buying on the counter came after a large deal took place in the pre-opening session. At 9:57 AM, Asian Paints shares were trading 2.06 per cent lower at ₹2,254 per share on the BSE. In comparison, the BSE Sensex was down 0.12 per cent at 82,412.64. The company's market capitalisation stood at ₹2,16,203.18 crore. Its 52-week high was at ₹3,394 per share and 52-week low was at ₹2,125 per share. Asian Paints block deal details According to data available on Bloomberg, 35 million shares changed hands in a single block deal on NSE in the market pre-opening session. This accounted for 3.65 per cent of equity. Block changed hands at ₹2,201 per share against last close of ₹2,208.8 per share. Buyers and sellers of the deals were not disclosed. As of quarter ending March 2025, India's mutual funds have a 5.67 per cent stake in Asian Paints at the end of the March quarter, with ICICI Prudential Mutual Fund holding at 1.24 per cent and SBI Mutual Fund at 1.51 per cent. Besides, Life Insurance Corporation of India holds 8.29 per cent stake in the company. The complaint was filed by Aditya Birla group in November last year, alleging that Asian Paints, which is the market leader with 53 per cent market share, had indulged in anti-competitive conduct and exclusionary practices. The allegations included restricting dealers from doing business with Grasim's Birla Opus. Grasim is a flagship company of the Aditya Birla group. It was also alleged that Asian Paints had put pressure on raw material suppliers to deny (supplies) or price-discriminate against Birla Opus.